Shares of Hims & Hers Health (NYSE: HIMS) sank 10.5% this week, according to data from S&P Global Market Intelligence. The ...

Eli Lilly announced plans to invest $27 billion in four new manufacturing sites in the United States. The pharma giant also ...

Hims & Hers Health has blazed a red-hot streak, helped by the growing popularity of weight-loss drugs. But after a massive ...

The BUZZ NextGen AI US Sentiment Leaders Index returned 2.66% during the month of January, compared to a return of 2.78% for the S&P 500 Index during the same period.

Eli Lilly is seeking to further cement its stance as a leader in weight loss drugs in an ad campaign calling out “unapproved” medications.

Eli Lilly is now offering four doses of Zepbound in self-administration vials. The lower-cost self-pay option targets people on Medicare and those who can no longer access compounded tirzepatide.

Eli Lilly is airing an ad during the Academy Awards urging customers to adopt a health skepticism when marketed drug brands that are not FDA-approved.

Once again, Eli Lilly is using Hollywood’s biggest night as a platform to speak out on a hot-button issue in pharma. | Once ...